Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00185757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Robert Negrin to Stanford University Trial status: Active, Not Recruiting to Completed · Enrollment target: estimated 20 to confirmed 21 · Study description expanded, about 8 wordsv13 Show 3 more changesShow less
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 20 to confirmed 21
    • Study description expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  2. Lead sponsor: Stanford University to Robert Negrin Trial status: Recruiting to Active, Not Recruiting · Interventions: infusion of activated T cells (Genetic) to Cytokine Induced Killer Cells (Drug) · Site details revised · 1 morev12 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Interventions: infusion of activated T cells (Genetic) to Cytokine Induced Killer Cells (Drug)
    • Site details revised
    • Study arms: 0 to 1
  3. Site contact updatedv11
  4. Re-verified, no change to tracked fieldsv10
  5. Primary and study completion dates: Dec 2012 Eligibility criteria revised · Secondary endpoints revised (3)v9 Show 2 more changesShow less
    • Eligibility criteria revised
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

Show 7 earlier versionsHide 7 earlier versions
  1. Eligibility criteria revised Site contact updatedv8 Show 1 more changeShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Jan 2004 to Jun 2004 Study site revised · Eligibility criteria shortened, about 2 wordsv7 Show 2 more changesShow less
    • Study site revised
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Collaborators expanded, about 5 wordsv6 See this version in full on ClinicalTrials.gov ↗
  4. Completion date: Apr 2004 to not stated Study description shortened, about 22 words · Eligibility criteria expanded, about 2 wordsv5 Show 2 more changesShow less
    • Study description shortened, about 22 words
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. 3 versions Re-verified since Mar 27, 2006, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1 dose escalation study evaluating the use of activated T-cells to treat relapsed malignancy (cancer) following allogeneic hematopoietic cell transplantation, without causing GvHD.
Trial Details
NCT Number NCT00185757
Lead Sponsor Stanford University
Collaborators: National Institutes of Health (NIH)
Conditions Multiple Myeloma, Blood and Marrow Transplant (BMT)
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov